14,436 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Griffith & Werner Inc.

Griffith & Werner Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,436 shares of the biopharmaceutical company’s stock, valued at approximately $1,333,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its position in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $28,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Stephens Consulting LLC boosted its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Gilead Sciences during the 4th quarter valued at $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,929 shares of company stock worth $5,644,780 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $107.37 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market cap of $133.56 billion, a price-to-earnings ratio of 290.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The stock has a fifty day simple moving average of $105.27 and a two-hundred day simple moving average of $100.30. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the business earned ($1.32) EPS. Gilead Sciences’s quarterly revenue was down .3% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.94%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Wall Street Analyst Weigh In

GILD has been the subject of several analyst reports. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Royal Bank of Canada increased their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.